The impact of unrestricted access to direct-acting antiviral among incarcerated hepatitis C virus-infected patients
- PMID: 33601868
- PMCID: PMC8273645
- DOI: 10.3350/cmh.2021.0015
The impact of unrestricted access to direct-acting antiviral among incarcerated hepatitis C virus-infected patients
Abstract
Background/aims: Despite the disproportionally high prevalence rates of hepatitis C virus (HCV) amongst the incarcerated population, eradication remains challenging due to logistic and financial barriers. Although treatment prioritization based on disease severity is commonly practiced, the efficacy of such approach remained uncertain. We aimed to compare the impact of unrestricted access to direct-acting antiviral (DAA) among incarcerated HCV-infected patients in Singapore.
Methods: In this retrospective study, we reviewed all incarcerated HCV-infected patients treated in our hospital during the restricted DAA era (2013-2018) and unrestricted DAA access era (2019). Study outcomes included the rate of sustained virological response (SVR), treatment completion and treatment default. Subgroup analysis was performed based on the presence of liver cirrhosis, HCV genotype and HCV treatment types.
Results: A total of 1,001 HCV patients was followed-up for 1,489 person-year. They were predominantly male (93%) with genotype-3 HCV infection (71%), and 38% were cirrhotic. The overall SVR during the restricted DAA access era and unrestricted DAA access era were 92.1% and 99.1%, respectively. Unrestricted access to DAA exponentially improved the treatment access among HCV-infected patients by 460%, resulting in a higher SVR rate (99% vs. 92%, P=0.003), higher treatment completion rate (99% vs. 93%, P<0.001) and lower treatment default rate (1% vs. 9%, P<0.001).
Conclusion: In this large cohort of incarcerated HCV-infected patients, we demonstrated that unrestricted access to DAA is an impactful strategy to allow rapid treatment up-scale in HCV micro-elimination.
Keywords: Antiviral agents; Hepatitis C, Chronic; Prisons.
Conflict of interest statement
The authors have no conflicts to disclose.
Figures




Similar articles
-
Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.J Hepatol. 2017 Jun;66(6):1173-1181. doi: 10.1016/j.jhep.2017.01.020. Epub 2017 Feb 2. J Hepatol. 2017. PMID: 28161470 Free PMC article.
-
Previous incarceration impacts access to hepatitis C virus (HCV) treatment among HIV-HCV co-infected patients in Canada.J Int AIDS Soc. 2018 Nov;21(11):e25197. doi: 10.1002/jia2.25197. J Int AIDS Soc. 2018. PMID: 30460791 Free PMC article.
-
Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.J Hepatol. 2019 Aug;71(2):281-288. doi: 10.1016/j.jhep.2019.04.014. Epub 2019 May 10. J Hepatol. 2019. PMID: 31078544
-
Systematic review with meta-analysis: effectiveness and tolerability of interferon-free direct-acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia.Aliment Pharmacol Ther. 2018 Mar;47(5):550-562. doi: 10.1111/apt.14507. Epub 2018 Jan 12. Aliment Pharmacol Ther. 2018. PMID: 29327780
-
Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy.Clin Mol Hepatol. 2020 Jul;26(3):251-260. doi: 10.3350/cmh.2020.0018. Epub 2020 Mar 19. Clin Mol Hepatol. 2020. PMID: 32188235 Free PMC article. Review.
Cited by
-
Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients.Clin Mol Hepatol. 2023 Jan;29(1):135-145. doi: 10.3350/cmh.2022.0181. Epub 2022 Sep 5. Clin Mol Hepatol. 2023. PMID: 36064306 Free PMC article.
-
HCV Infection and Liver Cirrhosis Are Associated with a Less-Favorable Serum Cholesteryl Ester Profile Which Improves through the Successful Treatment of HCV.Biomedicines. 2022 Dec 6;10(12):3152. doi: 10.3390/biomedicines10123152. Biomedicines. 2022. PMID: 36551908 Free PMC article.
-
Response to antiviral therapy for chronic hepatitis C and risk of hepatocellular carcinoma occurrence in Japan: a systematic review and meta-analysis of observational studies.Sci Rep. 2023 Mar 1;13(1):3445. doi: 10.1038/s41598-023-30467-5. Sci Rep. 2023. PMID: 36859564 Free PMC article.
-
Efficacy and safety of sofosbuvir/velpatasvir with or without ribavirin in hepatitis C genotype 3 compensated cirrhosis: A meta-analysis.World J Hepatol. 2022 Jun 27;14(6):1248-1257. doi: 10.4254/wjh.v14.i6.1248. World J Hepatol. 2022. PMID: 35978662 Free PMC article.
-
Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions.Nat Rev Gastroenterol Hepatol. 2024 Dec;21(12):834-851. doi: 10.1038/s41575-024-00967-4. Epub 2024 Aug 15. Nat Rev Gastroenterol Hepatol. 2024. PMID: 39147893 Review.
References
-
- Gallacher J, McPherson S. Progress towards micro-elimination of hepatitis C in the custodial setting. J Viral Hepat. 2021;28:300–301. - PubMed
-
- Institute for Criminal Policy Research (ICPR) World prison population list. Twelve editions. ICPR web site, < https://www.prisonstudies.org/>. Accessed 21 Sep 2020.
-
- Singapore Prison Service Singapore Prison Service Annual Report 2019. Singapore Prison Service web site, < https://www.sps.gov.sg>. Accessed 21 Sep 2020.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources